189 related articles for article (PubMed ID: 33931971)
1. Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer.
Gambaro K; Marques M; McNamara S; Couetoux du Tertre M; Diaz Z; Hoffert C; Srivastava A; Hébert S; Samson B; Lespérance B; Ko YJ; Dalfen R; St-Hilaire E; Sideris L; Couture F; Burkes R; Harb M; Camlioglu E; Gologan A; Pelsser V; Constantin A; Greenwood CMT; Tejpar S; Kavan P; Kleinman CL; Batist G
Clin Transl Med; 2021 Apr; 11(4):e401. PubMed ID: 33931971
[TBL] [Abstract][Full Text] [Related]
2. DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up.
Bigagli E; De Filippo C; Castagnini C; Toti S; Acquadro F; Giudici F; Fazi M; Dolara P; Messerini L; Tonelli F; Luceri C
Cell Oncol (Dordr); 2016 Dec; 39(6):545-558. PubMed ID: 27709558
[TBL] [Abstract][Full Text] [Related]
3. Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing.
Mogensen MB; Rossing M; Østrup O; Larsen PN; Heiberg Engel PJ; Jørgensen LN; Hogdall EV; Eriksen J; Ibsen P; Jess P; Grauslund M; Nielsen HJ; Nielsen FC; Vainer B; Osterlind K
BMC Cancer; 2018 Jul; 18(1):752. PubMed ID: 30029640
[TBL] [Abstract][Full Text] [Related]
4. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
[TBL] [Abstract][Full Text] [Related]
5. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
Zhou Q; Perakis SO; Ulz P; Mohan S; Riedl JM; Talakic E; Lax S; Tötsch M; Hoefler G; Bauernhofer T; Pichler M; Gerger A; Geigl JB; Heitzer E; Speicher MR
Genome Med; 2020 Feb; 12(1):20. PubMed ID: 32087735
[TBL] [Abstract][Full Text] [Related]
6. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
7. Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection.
Sveen A; Løes IM; Alagaratnam S; Nilsen G; Høland M; Lingjærde OC; Sorbye H; Berg KC; Horn A; Angelsen JH; Knappskog S; Lønning PE; Lothe RA
PLoS Genet; 2016 Jul; 12(7):e1006225. PubMed ID: 27472274
[TBL] [Abstract][Full Text] [Related]
8. Comparative genomic analysis of primary and synchronous metastatic colorectal cancers.
Lee SY; Haq F; Kim D; Jun C; Jo HJ; Ahn SM; Lee WS
PLoS One; 2014; 9(3):e90459. PubMed ID: 24599305
[TBL] [Abstract][Full Text] [Related]
9. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
10. Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.
Watson RG; Muhale F; Thorne LB; Yu J; O'Neil BH; Hoskins JM; Meyers MO; Deal AM; Ibrahim JG; Hudson ML; Walko CM; McLeod HL; Auman JT
Eur J Cancer; 2010 Dec; 46(18):3358-64. PubMed ID: 20727737
[TBL] [Abstract][Full Text] [Related]
11. Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients.
Fernandes FG; Silveira HCS; Júnior JNA; da Silveira RA; Zucca LE; Cárcano FM; Sanches AON; Neder L; Scapulatempo-Neto C; Serrano SV; Jonasch E; Reis RM; Evangelista AF
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668731
[TBL] [Abstract][Full Text] [Related]
12. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
[TBL] [Abstract][Full Text] [Related]
13. Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers.
Cho SY; Chae J; Na D; Kang W; Lee A; Min S; Kang J; Choi B; Lee J; Sung CO; Chuang JH; Lee C; Lee WS; Park H; Kim JI
Clin Cancer Res; 2019 May; 25(9):2821-2834. PubMed ID: 30670495
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
15. Genomic landscape of metastatic colorectal cancer.
Haan JC; Labots M; Rausch C; Koopman M; Tol J; Mekenkamp LJ; van de Wiel MA; Israeli D; van Essen HF; van Grieken NC; Voorham QJ; Bosch LJ; Qu X; Kabbarah O; Verheul HM; Nagtegaal ID; Punt CJ; Ylstra B; Meijer GA
Nat Commun; 2014 Nov; 5():5457. PubMed ID: 25394515
[TBL] [Abstract][Full Text] [Related]
16. Clinical-grade whole-genome sequencing and 3' transcriptome analysis of colorectal cancer patients.
Stodolna A; He M; Vasipalli M; Kingsbury Z; Becq J; Stockton JD; Dilworth MP; James J; Sillo T; Blakeway D; Ward ST; Ismail T; Ross MT; Beggs AD
Genome Med; 2021 Feb; 13(1):33. PubMed ID: 33632293
[TBL] [Abstract][Full Text] [Related]
17. Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays.
Muñoz-Bellvis L; Fontanillo C; González-González M; Garcia E; Iglesias M; Esteban C; Gutierrez ML; Abad MM; Bengoechea O; De Las Rivas J; Orfao A; Sayagués JM
Mod Pathol; 2012 Apr; 25(4):590-601. PubMed ID: 22222638
[TBL] [Abstract][Full Text] [Related]
18. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.
Mekenkamp LJ; Tol J; Dijkstra JR; de Krijger I; Vink-Börger ME; van Vliet S; Teerenstra S; Kamping E; Verwiel E; Koopman M; Meijer GA; van Krieken JH; Kuiper R; Punt CJ; Nagtegaal ID
BMC Cancer; 2012 Jul; 12():292. PubMed ID: 22804917
[TBL] [Abstract][Full Text] [Related]
19. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
Lin JK; Lin AJ; Lin CC; Lan YT; Yang SH; Li AF; Chang SC
J Surg Oncol; 2011 Nov; 104(6):661-6. PubMed ID: 21671463
[TBL] [Abstract][Full Text] [Related]
20. Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.
van Dijk E; Biesma HD; Cordes M; Smeets D; Neerincx M; Das S; Eijk PP; Murphy V; Barat A; Bacon O; Prehn JHM; Betge J; Gaiser T; Fender B; Meijer GA; McNamara DA; Klinger R; Koopman M; Ebert MPA; Kay EW; Hennessey BT; Verheul HMW; Gallagher WM; O'Connor DP; Punt CJA; Loupakis F; Lambrechts D; Byrne AT; van Grieken NCT; Ylstra B
J Clin Oncol; 2018 Jul; 36(20):2052-2060. PubMed ID: 29792754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
